Get the Stockscreener App
5.00
6.72%
-0.36
After Hours:
4.81
-0.19
-3.80%
Scisparc Ltd stock is traded at $5.00, with a volume of 11,600.
It is down -6.72% in the last 24 hours and down -37.81% over the past month.
SciSparc Ltd is a specialty clinical stage pharmaceutical company. It is engaged in developing several immunotherapy products and it owns patents in the immunotherapy field. It is focused on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. The company has two operating reportable segments; development of drugs based on cannabinoid molecules to be approved by an official regulatory authority (the company's operation); and online sales of a various range of hemp-based products including hemp gummies, hemp oil capsules, hemp gel, hemp cream, detox pills, height pills, antibacterial creams, and anti-aging creams, among other beauty and hair treatment products that are all manufactured in the United States.
See More
Previous Close:
$5.36
Open:
$5.1785
24h Volume:
11,600
Relative Volume:
0.01
Market Cap:
$2.87M
Revenue:
$856.00K
Net Income/Loss:
$-12.56M
P/E Ratio:
-0.0216
EPS:
-231.4926
Net Cash Flow:
$-4.14M
1W Performance:
+6.38%
1M Performance:
-37.81%
6M Performance:
-48.08%
1Y Performance:
-93.09%
1-Day Range:
$5.00
$5.2679
1-Week Range:
$4.23
$5.40
52-Week Range:
$2.98
$80.10
Scisparc Ltd Stock (SPRC) Company Profile
Compare SPRC vs VRTX, REGN, ARGX, RVMD, ALNY
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SPRC
Scisparc Ltd
|
5.00 | 3.07M | 856.00K | -12.56M | -4.14M | -231.49 |
VRTX
Vertex Pharmaceuticals Inc
|
485.65 | 123.36B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
676.69 | 71.18B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
860.55 | 53.68B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
186.16 | 38.09B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
267.47 | 37.80B | 4.29B | 577.22M | 641.34M | 4.2086 |
Scisparc Ltd Stock (SPRC) Latest News
SciSparc Ltd. (Nasdaq: SPRC) starts Phase IIb SCI-110 trial for Tourette - Stock Titan
NeuroThera starts Phase IIb trial in Germany fo... - Pluang
SciSparc Subsidiary NeuroThera Initiates Phase IIb SCI-110 Clinical Trial Site at Hannover Medical School for Adult Tourette Syndrome - Quiver Quantitative
Tourette treatment candidate SCI-110 enters testing at Hannover Medical School - Stock Titan
NeuroThera Labs Announces Initiation of Phase IIb Clinical Trial at Hannover Medical School in Germany for Innovative Treatment of Tourette Syndrome - TheNewswire
SciSparc (SPRC) Slips Over 7%: Support at $4.11 in Focus After Sharp DeclineWeak Sell Signals - dars.gov.et
SciSparc Ltd. (SPRC) details Alon Dayan RSUs and option in ownership update - Stock Titan
SciSparc Ltd. (SPRC) CEO Adler Oz updates Form 3 insider equity details - Stock Titan
SciSparc Ltd. (SPRC) director details RSU and option holdings in Form 3/A - Stock Titan
SciSparc Ltd. (SPRC) director revises Form 3, detailing RSU and option holdings - Stock Titan
SciSparc Ltd. (SPRC) CTO clarifies 5,528 RSU-linked shares and option terms - Stock Titan
SciSparc Ltd. (SPRC) Stock Price | Live Quotes & Charts | NASDAQ - timothysykes.com
SciSparc (SPRC) Surges Over 10% as Trading Activity Picks UpOrder Block - dars.gov.et
SPRC Stock Price, Quote & Chart - ChartMill
NeuroThera Labs Announces Upsize to Private Placement - TheNewswire
NeuroThera Labs Announces C$5,000,000 Private Placement of Units - TheNewswire
SciSparc (SPRC) Drops 6.7% as Shares Approach Critical Support ZoneETF Creation Redemption - dars.gov.et
SciSparc Company Profile & Introduction - Moomoo
Scisparc Ltd (SPRC) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Form 144 SciSparc Ltd. For: 22 June By Investing.com - Investing.com Australia
[144] SciSparc Ltd. SEC Filing - Stock Titan
SciSparc (SPRC) Suffers Sharp Decline: Key Support Levels Under PressureVolume Breakout Ideas - dars.gov.et
Scisparc Ltd (SPRC) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Scisparc Ltd (SPRC) Institutional Confidence - TradingKey
Scisparc Ltd (SPRC) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Scisparc Ltd (SPRC) Valuation: PE, PB & Fair Value Analysis - TradingKey
SPRC News | SCISPARC LTD (NASDAQ:SPRC) - ChartMill
Scisparc Ltd (SPRC) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Scisparc Ltd (SPRC) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Scisparc Ltd (SPRC) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Scisparc Ltd (SPRC) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
SciSparc Ltd. (SPRC) Slips 2.46% as Shares Test Near-Term Support at $7.92Composite Profile - dars.gov.et
SciSparc Ltd. Ordinary Shares Stock Short Interest Rises to 66.94% - Moomoo
SciSparc Ltd.'s Equity Buyback announced on July 7, 2022, has expired. - marketscreener.com
Why is SciSparc stock skyrocketing on Thursday? - MSN
SciSparc more than doubles as NeuroThera wins conditional nod for CliniQuantum deal - MSN
NeuroThera completes acquisition of 54% stake in CliniQuantum - Investing.com UK
In today's session, these stocks are experiencing unusual volume. - ChartMill
Which stocks are gapping on Thursday? - ChartMill
SPRC Stock Pops As SciSparc Pushes Into Quantum Clinical Analytics - timothysykes.com
SciSparc Subsidiary NeuroThera Labs Closes Majority Acquisition of CliniQuantum - TipRanks
These stocks that are showing activity before the opening bell on Thursday. - ChartMill
NeuroThera completes acquisition of 54% stake in CliniQuantum By Investing.com - Investing.com India
SciSparc (NASDAQ: SPRC) unit NeuroThera acquires 54% of CliniQuantum in CAD$9.46M share deal - Stock Titan
Quantum trial-analysis startup CliniQuantum sold in C$9.5M SciSparc deal - Stock Titan
SciSparc Ltd. Subsidiary NeuroThera Labs Inc. Completes Acquisition of 54% Stake in CliniQuantum Ltd. - Quiver Quantitative
NeuroThera Labs Inc. Announces Closing of Acquisition of Majority Stake in CliniQuantum Ltd. - Yahoo Finance
Neurothera Labs Inc. Announces Closing Of Acquisition Of Majority Stake In Cliniquantum Ltd. - marketscreener.com
SciSparc's Quantum Gambit: Betting on AI to Remake Drug Trials - BriefGlance
Director Itschak Shrem Sells Shares of SciSparc Ltd (SPRC) - GuruFocus
SciSparc (SPRC) director Itschak Shrem sells 462 Ordinary Shares at $10 - Stock Titan
Scisparc Ltd Stock (SPRC) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.80%
2.11%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):